Professor Jun Takahashi’s famous laboratory at CiRA (Kyoto, Japan) is using the MACSQuant Tyto Cell Sorter for GMP-compliant sorting of iPSC-derived dopaminergic progenitors in a new trial for Parkinson’s disease.
So how did the MACSQuant Tyto Cell Sorter come to be involved and what difference did it make?
Well, in the initial clinical trial Prof. Takahashi’s group made use of a conventional droplet-based cell sorting system to isolate the iPSC-derived progenitors its treatment required. However, both handling and sort performance left a lot to be desired: bad cellular yields and a literally exhaustive amount of hands-on time proved a massive burden for the operators, with sorting vials requiring exchange every 10 minutes for 16 straight hours.
You can judge for yourself from the data shown on Prof. Takahashi’s poster, presented at ISSCR 2019 in Los Angeles, USA.
Spoiler alert: post-sorting cell survival was increased with the MACSQuant Tyto, contributing to a higher yield of final cell product, whilst the estimated time to producing cells required for one patient was reduced by more than a third.
In other words, more product was developed faster, allowing it to get to patients’ bedsides more quickly.